Physician profile
Michael Pennington
NPI 1689617755
$2,423.70
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,458 · 2020: $773 · 2021: $118 · 2022: $75.54.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $460.16 | 2019-2021 | |
| Allergan, INC. | $335.78 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $300.21 | 2019-2022 | |
| Novo Nordisk INC | $294.46 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $251.50 | 2019-2020 | |
| Amgen INC. | $196.56 | 2019-2020 | |
| Lilly USA, LLC | $190.99 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $91.60 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $41.08 | 2020-2021 | |
| Jazz Pharmaceuticals INC. | $38.04 | 2020-2021 | |
| Radius Health, INC. | $32.19 | 2020 | |
| Dexcom, INC. | $29.48 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.38 | 2019 | |
| Glaxosmithkline, LLC. | $23.83 | 2019 | |
| Abbvie INC. | $23.78 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $18.14 | 2019 | |
| Upsher-Smith Laboratories LLC | $16.70 | 2022 | |
| Abbott Laboratories | $14.12 | 2022 | |
| Amarin Pharma, INC. | $13.27 | 2020 | |
| Merck Sharp & Dohme LLC | $12.61 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.82 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Pennington listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.